All News

The FDA approved subcutaneous amivantamab with recombinant human hyaluronidase for EGFR-mutated NSCLC based on the phase 3 PALOMA-3 trial.

Advancements in 2025 in non-Hodgkin lymphoma treatments focused on bringing CAR T-cell therapy and bispecific antibodies into the community setting.

The meeting included new evidence and expert insights on hormone therapy, AI, and the expanding role of GLP-1 therapies in cardiovascular care.

A study using Mendelian randomization found higher BMI and IBD have causal links to hidradenitis suppurativa risk.

Rucaparib’s full approval for BRCA-mutated mCRPC is supported by data showing significant gains in radiographic progression-free survival.

Reflect on the challenges in health equity, care access, and policy shifts impacting health insurance and clinical research in 2025.

A last-minute push to extend Affordable Care Act subsidies was stopped as GOP leadership prevented an expedited vote, leaving the future of the subsidies uncertain.

These were the most-read articles on alopecia areata in 2025.

Twice-yearly depemokimab cuts asthma exacerbations in phase 3 trials for patients aged 12 and older with severe eosinophilic asthma.

Intranasal etripamil was approved to self-treat episodes of paroxysmal supraventricular tachycardia, supported by phase 3 RAPID trial data.

Explore safe IBD treatment options for patients with chronic kidney disease, focusing on tailored approaches to optimize kidney health and medication efficacy.

A new study finds patients with unmet social needs like housing or transportation face higher ED and inpatient use and that resolving these needs may reduce utilization.

With ACA subsidies expiring, experts warn coverage losses could worsen access to behavioral health care and emergency department strains.

Our top conference coverage of the year highlighted findings presented at CROI 2025, ACCC Spring, and EHA, among others.

High response rates, strong R0 resection, and low severe adverse events with neoadjuvant therapy plus immunotherapy were identified in a rectal cancer study.

Our top content from the World Conference on Lung Cancer (WCLC) 2025 featured new therapeutic strategies for EGFR+ NSCLC and trial results on amivantamab.

The past year has seen multiple changes in the HIV space that have long-term effects when it comes to ending the epidemic.

This year’s most-read articles on CKD highlighted research and insights on drug approvals, guidelines, and value-based care.

Today, the FDA issued new guidance allowing de-identified real-world evidence in certain medical device applications, removing a barrier to using large data sources.

The FDA approved trastuzumab deruxtecan plus pertuzumab for first-line HER2-positive metastatic breast cancer after DESTINY-Breast09 showed major PFS gains.

The ustekinumab biosimilar DMB-3115 matched reference therapy in efficacy and safety for moderate to severe plaque psoriasis, according to a phase 3 trial.

COVID-19 vaccination during pregnancy lowers hospitalization and preterm birth risks, providing key guidance for maternal care strategies.

Our top breast cancer stories in 2025 covered FDA approvals, new and failed therapies, screening gaps, and policy factors shaping treatment access and outcomes.

AHA 2025 highlights included new guidelines and targeted approaches advancing heart failure and cardiovascular care.

The patient was a rare case of a patient with dedifferentiated liposarcoma and a high tumor mutational burden.

Top articles in 2025 covered advancements in acute myeloid leukemia treatments, including allogeneic CAR T-cell therapy.

Eunice Wang, MD, highlights breakthroughs in menin inhibitors for acute leukemias, showcasing promising combination therapies and addressing treatment challenges at ASH 2025.

New research reveals teclistamab and daratumumab significantly enhance progression-free survival in multiple myeloma, reshaping treatment standards.